CRISPR corrects X-linked granulomatous disease in a mouse model

Andrew Han, GenomeWeb,

In a new article published in the journal Science Translational Medicine (, researchers used CRISPR to correct a mutation in NOX2 that causes X-linked granulomatous disease ex vivo, followed by implantation into a mouse model.  Mice implanted with the edited cells demonstrated functional NOX2 protein for up to 5 months, demonstrating the potential CRISPR has in treating genetic disorders.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply